

Name: Nullin Divecha (Professor in cellular signalling)**Education**

1982-1985	Bsc	Biochemistry Manchester University.
1985-1988	Ph.D	Biochemistry Sheffield University.

Positions held.

1988-1993	Postdoctoral fellow	Prof Rf.Irvine	The Babraham Institute
1993-1997	Babraham Fellow	Group leader	The Babraham Institute
1997-2003	Junior Group leader		The Netherlands Cancer Institute
2003-2007	Senior Group Leader		The Netherlands Cancer Institute
2007-2014	Senior Group Leader		The Paterson institute for cancer Res
2014-2016	Associate Professor.		Southampton University
2015-2016	EU Marie Curie fellow		INGM Milan
2016-	Professor in cell signalling		University of Southampton

Prizes and awards and positions:**The Babraham Institute**

1992:	Awarded the Babraham research fellowship.
1994-1997:	co-authored (with Prof. Irvine) two project grants from the BBSRC and subsequently supervised two postdoctoral researchers

Netherlands Cancer Insitute:

1997:	Awarded the AVL fellowship
1999-2003:	KVF grant (Dutch cancer society) Nuclear phosphoinositide signalling.
2000-2004:	KVF with Dr. Wim Van Blitterswijk to fund two people: DAG kinase
2002-2006:	KVF grant to fund two people. PIP5K and cellular stress
2005-2009:	KVF grant to fund two people. Role of PtdIns5P/PIP4K in regulating p53 function

Paterson Institute for cancer research

2007-2013	Core funding from CRUK.
-----------	-------------------------

University of Southampton:

2014-	Awarded but refused an INSERM DR2 directors position at the I2MC
2014-2016:	Awarded an EU Marie-Curie experienced Research fellowship
2016	Awarded BBSRC grant BB/P003508/1 The role of Nuclear phosphoinositides in epigenetic signalling
2016	Awarded BBSRC grant BB/N016823/1 Investigating the role of PIP4K2B, nuclear phosphoinositides and TAF3 in transcription and genome organisation during myogenic differentiation
2016-2019:	Ph.D. studentship from the Malaysian government
2019	Ph.D. studentship from Biological Sciences

Positions of Esteem

2016-	Theme lead for molecular and cellular Biosciences.
2016-	Senior member of the Research Strategy group in Biological Sciences
2018-	Co-lead Cell biology in life sciences drive.
2021	member of UOS implementation of BBRSC initiatives

Conferences organised.

2007	Vice Chair	Gordon conference on nuclear signalling
2009	Co-Chair	Gordon conference on nuclear signalling
2011	Co-chair	Keystone Symposia: Inositide Signaling and PtdIns3P Kinases

Invited international Conference seminars (2007-).

2007	Gordon conference on nuclear signalling
2007	Babraham Institute Signal transduction meeting

- 2007 GRC "Signal Transduction within the Nucleus, CA, USA; Janilia Conferences, Washington DC, USA
- 2009 Gordon conference on nuclear signalling
- 2009 FEBS Lipid signalling in disease Ortona, Italy
- 2009 Mt.St. Odile 34th Symposium Inositide metabolism, France
- 2010 Japanese biochemical society meeting BM2010 (Tokyo) and DGK satellite meeting (Kobe)
- 2010 Advances in enzyme regulation (Bologna)
- 2011 Gordon conference on nuclear signalling, Ventura
- 2011 Keystone symposia Inositide signalling (USA)
- 2012 Faseb: Lipid signalling, Vermont
- 2012 Advances in Biological regulation (Bologna)
- 2012 FEBS Lipid Signalling (Vico Equense, Italy)
- 2012 Inositide signalling in health and disease (Coorg Bangalore India)
- 2014 European Symposium on Hormones and Cell Regulation (Mt St Odile Strasbourg)
- 2015 ASBMB (Boston USA)
- 2015 Biochemical society lipid signalling meeting UK
- 2015 Advances in biological regulation: Bologna
- 2015 Chromatin Signalling Keynote speaker: London chromatin club
- 2016 FASEB: phospholipid Signaling in Cancer, neurodegeneration and cardiovascular
- 2017 Special ABR symposium: Ulsan Korea
- 2019 Advances in biological regulation: Bologna

Publications.

1. Andrews, D.M., et al., *Identification and optimization of a novel series of selective PIP5K inhibitors*. **Bioorg Med Chem**, 2021. **54**: p. 116557.
2. Poli, A., et al., *PIP4Ks impact on PI3K, FOXO3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity*. **Proc Natl Acad Sci U S A**, 2021. **118**(31).
3. Ratti, S., et al., *"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia"*. **Front Oncol**, 2021. **11**: p. 678824.
4. Poli, A., et al., *Exploring the controversial role of PI3K signalling in CD4(+) regulatory T (T-Reg) cells*. **Adv Biol Regul**, 2020. **76**: p. 100722.
5. Bowler, E.H., et al., *Deep proteomic analysis of Dnmt1 mutant/hypomorphic colorectal cancer cells reveals dysregulation of epithelial-mesenchymal transition and subcellular re-localization of Beta-Catenin*. **Epigenetics**, 2020. **15**(1-2): p. 107-121.
6. Bowler, E.H., et al., *Proteomic Analysis of Azacitidine-Induced Degradation Profiles Identifies Multiple Chromatin and Epigenetic Regulators Including Uhrf1 and Dnmt1 as Sensitive to Azacitidine*. **J Proteome Res**, 2019. **18**(3): p. 1032-1042.
7. Poli, A., et al., *Phosphatidylinositol 5 Phosphate (PI5P): From Behind the Scenes to the Front (Nuclear) Stage*. **Int J Mol Sci**, 2019. **20**(9).
8. Fiume, R., et al., *Nuclear Phosphoinositides: Their Regulation and Roles in Nuclear Functions*. **Int J Mol Sci**, 2019. **20**(12).
9. Lundquist, M.R., et al., *Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy*. **Mol Cell**, 2018. **70**(3): p. 531-544 e9.
10. Stijf-Bultsma, Y., et al., *The basal transcription complex component TAF3 transduces changes in nuclear phosphoinositides into transcriptional output*. **Mol Cell**, 2015. **58**(3): p. 453-67.
11. Gelato, K.A., et al., *Accessibility of different histone H3-binding domains of UHRF1 is allosterically regulated by phosphatidylinositol 5-phosphate*. **Mol Cell**, 2014. **54**(6): p. 905-19.